Naosuke NAKAMURA, a,1) Shinya TOBA, a,1) Mitsuharu HIRAI, a Shinichi MORISHITA, a Tadahisa MIKAMI, the product was digested with SacI. All cDNA fragments thus obtained were mixed together and ligated by T4 ligase (Promega), obtaining pFastFHGP67 that codes for the GP67 secretion signal and the FLAG/His tags. Human pt-GalNAc-T cDNA deleted of the sequence for the cytosolic domain and the transmembrane region was prepared as outlined previously, 21) and inserted into the NotI and XbaI sites of pFastFHGP67. The isolated clone was used for transformation of the host strain E. coli DH10Bac TM . The amplification of recombinant baculoviruses and expression of the recombinant pt-GalNAc-T were carried out according to the instructions described in the manual of the Bac-to-Bac ® Baculovirus expression system (Invitrogen).
Assay for Transferase Activity Three days after the transfection of High Five cells with the recombinant baculoviruses, the conditioned medium was recovered, dialyzed, and mixed with Ni-NTA agarose. After incubation overnight, recombinant pt-GalNAc-T was eluted with 25 mM Tris-HCl buffer (pH 7.2), containing 100 mM NaCl and 500 mM imidazole. The enzyme activity was determined as described previously.
21)
Northern Blot Analysis For the analysis of the human clone, human brain Multiple Tissue Northern blot II (Clontech) was hybridized with a digoxigenin-labeled probe of human pt-GalNAc-T, and detected as previously described. 12) For the analysis of the rat clone, five micrograms of rat total RNA (Origene) was electrophoresed on a 1% agarose gel. RNA was, then, transferred to a positively charged nylon membrane (Roche), and hybridized with a digoxigenin-labeled rat probe.
In Situ Hybridization Saggital sections of Wistar rat embryos (E19.5) were hybridized with 35 S-cRNA antisense probe as described previously. 22) 
RESULTS
In order to clone genes for the GalNAc-transferase family, homology-based PCR, in combination with 5Ј-and 3Ј-RACE, using the nucleotide sequence of human GalNAc-T9, was carried out, and a full-length cDNA clone was obtained from rat brain. Among the cloned GalNAc-transferases, this clone was most homologous to GalNAc-T9 with 77% amino acid similarity. We, then, cloned its human orthologue by PCR using the nucleotide sequence obtained in the database search. The amino acid sequence of the human clone obtained was 98% homologous to that of the rat clone. These clones were referred to as the putative GalNAc-transferases (designated pt-GalNAc-T), since they had structural features conserved in the GalNAc-transferase family, though their transferase activity has not been detected yet as described below. Figure 1 shows the predicted amino acid sequences of human and rat pt-GalNAc-Ts in comparison with human GalNAc-T9. They contained an open reading frame encoding a type II membrane protein consisting of 598 amino acid residues with a 7-amino acid N-terminal cytoplasmic domain, a 20-amino acid transmembrane domain, a 92-amino acid stem region, and a 479-amino acid putative catalytic re- The alignment was performed using the pairwise and multiple Clustal W (1.4) method in MacVector. The parameters for the alignment were: slow alignment, open gap penaltyϭ10, extend gap penaltyϭ0.05, matrixϭblosum 30, delay divergeneϭ10%, and no hydrophile gap penalty. The DXH sequence in the glycosyltransferase 1 motif is outlined. Conserved acidic, histidine, and cysteine residues are indicated by ᭹, ᭛, and ᭝, respectively. gion. They had several characteristics commonly found in the GalNAc-transferase family: 1) a glycosyltransferase 1 (GT1) motif, a conserved sequence commonly found in glycosyltransferases, 23) 2) a DXH sequence in the GT1 motif, a putative binding site for a sugar donor and/or a metal ion, 24) 3) a Gal/GalNAc-T motif consisting of about 40 amino acid residues, 23) 4) conserved acidic, histidine, and cysteine residues, 23, 25, 26) and 5) (QXW) 3 repeats, a C-terminal lectinlike domain. 27) We, then, investigated the expression of pt-GalNAc-T. First, the expression of human pt-GalNAc-T in the brain was examined by Northern blot analysis. Figure 2a shows that it was strongest in cerebral cortex. The level of expression in cerebellum, occipital pole, frontal lobe, temporal lobe, and putamen was moderate. This is in contrast with human GalNAc-T9, which is expressed most abundantly in cerebellum, and to a lesser extent in cerebral cortex. 12) The mRNA expression of rat pt-GalNAc-T was also investigated in adult rats. Figure 2b shows that two distinct transcripts of rat pt-GalNAc-T (a major 2.0-kb transcript and minor 5.0-kb transcript) were exclusively expressed in the brain. It should be noted that a significant amount of human orthologue mRNA is found in the heart as well. 19) It may be possible that more sensitive methods such as RT-PCR may detect a small amount expression of rat pt-GalNAc-T in the heart, although Northern blot analysis did not reveal any transcripts. To examine the mRNA expression in rat embryos, sagittal sections of E19.5 embryos were analyzed (Fig.  2c) . A strong discrete hybridization signal was detected in the diencephalon (thalamus), cerebellar primordium, and dorsal root ganglion. This demonstrates that the expression of rat pt-GalNAc-T mRNA in rat embryos as well as adult rats was confined to the nervous system. Rat pt-GalNAc-T expression was, therefore, initiated at least by the late embryonic stage, and the rat brain may require continuous ptGalNAc-T expression in the embryonic and adult stages.
To examine the mRNA expression in the rat brain in more detail, coronal sections of the adult brain were analyzed by in situ hybridization with a 35 S-labeled antisense or sense cRNA probe. Rat pt-GalNAc-T was preferentially expressed in CA1, CA2, and CA3 in the hippocampus, intermediate layers of the cerebral cortex, and thalamus (Fig. 3a) . It was also strongly expressed in the cerebellum (Fig. 3b) . We, then, examined microautoradiographic images of rat brain sections subjected to in situ hybridization. In these sections, cells in the tissues were located by Nissl staining. Strong expression of rat pt-GalNAc-T mRNA was observed in CA3 and the granular layer of the dentate gyrus in the hippocampus (Figs.  3c, d) , and the granule cell layer in the cerebellum (Figs.  3e, f) . Figure 4 shows high magnification images of the in situ hybridization sections. With Nissl staining of brain sections, glial cells appeared as small intensely stained (dark) cells. In contrast, neurons were generally larger and less intensely stained (lighter) owing to their volume. 28) Analysis of the sections clearly revealed that the grains of the hybridized antisense probe were exclusively associated with neurons (Figs. 4a, b) . These observations demonstrated that rat ptGalNAc-T was expressed in neurons, but not in glial cells, in certain regions of the brain.
Finally we assayed the catalytic activity of human ptGalNAc-T. For this, a truncated pt-GalNAc-T, which lacks the cytoplasmic tail and transmembrane region, but has FLAG and 6xHis tags at the N-terminus, was expressed in insect cells. The recombinant proteins in the culture medium were recovered and purified with Ni ϩ -agarose, and then assayed for the activity. Recombinant pt-GalNAc-T, however, did not glycosylate peptides derived from mammalian mucins, such as MUC1a (AHGVTSAPDTR), MUC5AC (GTTPDPVPTTG), and MUC7 (TTAAPPTPSAG), while recombinant rat GalNAc-T1 did (data not shown). Judging (c) and (e) Light field images, and (d) and (f) dark field images. Cx, cerebral cortex; CA1, CA1 region of hippocampus; CA2, CA2 region of hippocampus; CA3, CA3 region of hippocampus; DG, dentate gyrus; t, thalamus; GrDG, granular layer of dentate gyrus; MoDG, molecular layer of dentate gyrus; GrCL, granular cell layer; MoL, molecular layer.
from its restricted distribution in neurons, pt-GalNAc-T may not glycosylate typical mucin-type molecules, but catalyze brain-specific O-glycosylation.
DISCUSSION
We cloned cDNAs from human and rat, which are most homologous to GalNAc-T9. These clones (pt-GalNAc-Ts) contained the structural features characteristic of GalNActransferases. Hence, it is expected that they encode active GalNAc-transferases, but they did not exhibit biochemical transferase activity when assayed using peptides with typical mucin polypeptide sequences. The failure to detect the catalytic activity of pt-GalNAc-T may result from several causes. First of all, pt-GalNAc-T may be a member of socalled follow-up type isozymes, which requires partial glycosylation of the acceptors in order to recognize them as substrates. In fact, prior glycosylation of the acceptor peptides was reported to be a prerequisite for glycosylation by GalNAc-T4, -T7, and -T10. 7, 10, 13) Secondly, the transmembrane region of pt-GalNAc-T may be involved in the activity. Expression of the recombinant soluble molecules, therefore, may have generated inactive enzymes. Thirdly, pt-GalNAc-T may belong to other glycosyltransferase families involved in the transfer of different monosaccharides. It is, however, unlikely that pt-GalNAc-T catalyzes reactions other than GalNAc transfer, since it has motif structures of GalNActransferase families, exhibiting very high homology (77%) to GalNAc-T9. Finally, judging from their restricted expression in the brain, pt-GalNAc-T may have a narrow substrate specificity for catalyzing brain-specific glycosylation. Peptides containing typical mucin-like sequences may not function as acceptors.
In fact, there are several examples of O-glycosylated glycoproteins in the brain. Tenascin-R is a brain glycoprotein with a disialylated core-1 structure, Siaa2→3Galb1→ 3(Siaa2→6)GalNAc, as a major carbohydrate chain, and is expressed in the spinal cord, cerebellum, hippocampus, and olfactory bulb, colocalizing with rat pt-GalNAc-T except in the olfactory bulb. 29, 30) Chromogranin A (CgA) is also found in the brain and spinal cord, as well as in the endocrine and immune systems. 31) In situ hybridization of CgA mRNA in rat brain sections revealed the expression to be strongest in the pyramidal cell layer of the hippocampus and the subiculum, 31) where rat pt-GalNAc-T is abundantly expressed as well. b-Amyloid precursor protein (APP) is another example of an O-glycosylated protein in the brain. 32 ) Both CgA and APP are known to accumulate in extracellular b-amyloid plaques in Alzheimer's disease. 31, 33) CgA is also reported to accumulate in patients with Parkinson's disease and Pick's disease. [34] [35] [36] O-Glycosylation of a-synuclein is reported as well.
37) a-Synuclein is a major component of intracellular fibrillary aggregates and implicated in the pathogenesis of Parkinson's disease. 38) Aberrant O-glycosylation may cause the conformational change in a-synuclein, resulting in the deposition of abnormal filaments. Although the relationship of pt-GalNAc-T with these pathological conditions is not clear, it is possible that the deposition of these proteins in the brain is related to altered O-glycosylation. Some of these glycoproteins colocalize with pt-GalNAc-T in the brain, thus raising the possibility that they might be endogenous substrates of pt-GalNAc-T. Studies using synthetic peptides derived from the potential O-glycosylation sites of these glycoproteins are in progress.
Human pt-GalNAc-T was found to be located in the WBS critical region, and defined as WBSCR17. 19) There are several genes in this region, and concomitant deletion of several WBSCR genes, not a single gene, is possibly involved in the pathogenesis of WBS. 20, 39) It is also reported that in WBS patients, the brain is significantly smaller, and the cerebellum is enlarged relative to the cerebrum. 40) The strong expression of both rat and human pt-GalNAc-Ts in these regions, together with the continual expression of the rat clone throughout the embryo and adult brain, suggests essential roles in the normal development of the brain. Therefore, the deletion of ptGalNAc-T together with other WBSCR genes may be related to the developmental disorder found in WBS. 
